KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Short-Term Debt issuances (2017 - 2025)

Amneal Pharmaceuticals (AMRX) has 7 years of Short-Term Debt issuances data on record, last reported at $218.0 million in Q1 2025.

  • For Q1 2025, Short-Term Debt issuances rose 354.17% year-over-year to $218.0 million; the TTM value through Dec 2025 reached $218.0 million, up 354.17%, while the annual FY2025 figure was $218.0 million, 354.17% up from the prior year.
  • Short-Term Debt issuances reached $218.0 million in Q1 2025 per AMRX's latest filing, up from $48.0 million in the prior quarter.
  • Across five years, Short-Term Debt issuances topped out at $218.0 million in Q1 2025 and bottomed at $10.0 million in Q3 2023.
  • Average Short-Term Debt issuances over 4 years is $81.4 million, with a median of $80.0 million recorded in 2023.
  • Peak YoY movement for Short-Term Debt issuances: crashed 76.47% in 2023, then surged 354.17% in 2025.
  • A 4-year view of Short-Term Debt issuances shows it stood at $85.0 million in 2022, then rose by 28.24% to $109.0 million in 2023, then tumbled by 55.96% to $48.0 million in 2024, then soared by 354.17% to $218.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short-Term Debt issuances were $218.0 million in Q1 2025, $48.0 million in Q1 2024, and $109.0 million in Q4 2023.